Donald R Vandevanter

List of Publications by Year
in descending order

88 papers	4,329 citations	126907 33 h-index	110387 64 g-index
88 all docs	88 docs citations	88 times ranked	4190 citing authors

#	Article	IF	Citations
1	Retracing changes in cystic fibrosis understanding and management over the past twenty years. Journal of Cystic Fibrosis, 2022, 21, 3-9.	0.7	3
2	Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations. Journal of Cystic Fibrosis, 2022, , .	0.7	2
3	Antipseudomonal treatment decisions during CF exacerbation management. Journal of Cystic Fibrosis, 2022, 21, 753-758.	0.7	4
4	Changes in airway bacterial communities occur soon after initiation of antibiotic treatment of pulmonary exacerbations in cystic fibrosis. Journal of Cystic Fibrosis, 2022, , .	0.7	6
5	Antimicrobial resistance: Concerns of healthcare providers and people with CF. Journal of Cystic Fibrosis, 2021, 20, 407-412.	0.7	13
6	Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 257-263.	0.7	7
7	Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials. Journal of Cystic Fibrosis, 2021, 20, 39-45.	0.7	9
8	Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment. Journal of Cystic Fibrosis, 2021, 20, 36-38.	0.7	7
9	Epidemiologic Study of Cystic Fibrosis: 25 years of observational research. Pediatric Pulmonology, 2021, 56, 823-836.	2.0	11
10	Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study. Journal of Cystic Fibrosis, 2021, 20, 965-971.	0.7	11
11	The march towards CFTR modulator access for all people with CF: The end of the beginning. Journal of Cystic Fibrosis, 2021, 20, 185-187.	0.7	1
12	Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis. Future Microbiology, 2021, 16, 1087-1104.	2.0	7
13	A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1295-1305.	5.6	45
14	Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. Journal of Cystic Fibrosis, 2020, 19, 370-375.	0.7	24
15	Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis. Pediatric Pulmonology, 2020, 55, 828-834.	2.0	21
16	Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations. Annals of the American Thoracic Society, 2020, 17, 1590-1598.	3.2	8
17	Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes. European Respiratory Journal, 2020, 55, 2000105.	6.7	1
18	Building global development strategies for cf therapeutics during a transitional cftr modulator era. Journal of Cystic Fibrosis, 2020, 19, 677-687.	0.7	24

#	Article	IF	Citations
19	Finding the relevance of antimicrobial stewardship for cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 511-520.	0.7	18
20	Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis, 2020, 19, 595-601.	0.7	49
21	CFTR modulator theratyping: Current status, gaps and future directions. Journal of Cystic Fibrosis, 2019, 18, 22-34.	0.7	208
22	Measures of Cystic Fibrosis Airway Microbiota during Periods of Clinical Stability. Annals of the American Thoracic Society, 2019, 16, 1534-1542.	3.2	26
23	The Pitfalls of Polypharmacy and Precision Medicine in Cystic Fibrosis. Annals of the American Thoracic Society, 2019, 16, 819-820.	3.2	1
24	Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review. Journal of Cystic Fibrosis, 2019, 18, 236-243.	0.7	84
25	Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities. Annals of the American Thoracic Society, 2019, 16, 534-539.	3.2	33
26	The use of antimicrobial susceptibility testing in pediatric cystic fibrosis pulmonary exacerbations. Journal of Cystic Fibrosis, 2019, 18, 851-856.	0.7	12
27	Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. Clinical Infectious Diseases, 2019, 69, 1812-1816.	5.8	62
28	Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis. Annals of the American Thoracic Society, 2018, 15, 485-493.	3.2	52
29	Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF. Contemporary Clinical Trials, 2018, 64, 35-40.	1.8	42
30	Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change. Pediatric Pulmonology, 2018, 53, 43-49.	2.0	6
31	Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary Exacerbations. Annals of the American Thoracic Society, 2018, 15, 225-233.	3.2	32
32	Defining antimicrobial resistance in cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 696-704.	0.7	66
33	Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis. PLoS ONE, 2018, 13, e0194060.	2.5	76
34	BMI fails to identify poor nutritional status in stunted children with CF. Journal of Cystic Fibrosis, 2017, 16, 158-160.	0.7	20
35	The challenges of maintaining momentum in CF drug development and approval - Commentary. Journal of Cystic Fibrosis, 2017, 16, 170-171.	0.7	1
36	Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations. Journal of Cystic Fibrosis, 2017, 16, 600-606.	0.7	76

#	Article	IF	Citations
37	Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations. Journal of Cystic Fibrosis, 2017, 16, 592-599.	0.7	69
38	Feasibility of placebo-controlled trial designs for new CFTR modulator evaluation. Journal of Cystic Fibrosis, 2017, 16, 496-498.	0.7	15
39	Relationship of Antibiotic Treatment to Recovery after Acute FEV₁ Decline in Children with Cystic Fibrosis. Annals of the American Thoracic Society, 2017, 14, 937-942.	3.2	35
40	Comparison of FEV1 reference equations for evaluating a cystic fibrosis therapeutic intervention. Pediatric Pulmonology, 2017, 52, 1013-1019.	2.0	6
41	Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies. Current Opinion in Pulmonary Medicine, 2017, 23, 530-535.	2.6	8
42	Anti-Infective Therapies in Cystic Fibrosis. Milestones in Drug Therapy, 2017, , 153-169.	0.1	0
43	IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 372-379.	0.7	35
44	Potential for Therapeutic Benefit among Cystic Fibrosis Populations Excluded from Clinical Trials or Labeling of Marketed Therapies. Annals of the American Thoracic Society, 2016, 13, 1890-1893.	3.2	2
45	Efficacy measures for clinical trials: A review series. Journal of Cystic Fibrosis, 2016, 15, 415.	0.7	1
46	CFTR modulators and pregnancy: Our work has only just begun. Journal of Cystic Fibrosis, 2016, 15, 6-7.	0.7	15
47	Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 783-790.	0.7	34
48	A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. Journal of Cystic Fibrosis, 2016, 15, 495-502.	0.7	59
49	Culture-Based and Culture-Independent Bacteriologic Analysis of Cystic Fibrosis Respiratory Specimens. Journal of Clinical Microbiology, 2016, 54, 613-619.	3.9	48
50	Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Journal of Cystic Fibrosis, 2016, 15, 634-640.	0.7	40
51	Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. Journal of Pediatrics, 2016, 169, 116-121.e2.	1.8	44
52	Cystic fibrosis in young children: A review of disease manifestation, progression, and response to early treatment. Journal of Cystic Fibrosis, 2016, 15, 147-157.	0.7	108
53	Decline in lung function does not predict future decline in lung function in cystic fibrosis patients. Pediatric Pulmonology, 2015, 50, 856-862.	2.0	19
54	Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis. Journal of Cystic Fibrosis, 2015, 14, 720-726.	0.7	51

#	Article	IF	Citations
55	A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 507-514.	0.7	62
56	Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes. Journal of Cystic Fibrosis, 2015, 14, 370-375.	0.7	24
57	In Vitro Antibiotic Susceptibility of Initial Pseudomonas aeruginosa Isolates From United States Cystic Fibrosis Patients. Journal of the Pediatric Infectious Diseases Society, 2015, 4, 151-154.	1.3	6
58	Antibiotic treatment of signs and symptoms of pulmonary exacerbations: A comparison by care site. Pediatric Pulmonology, 2015, 50, 431-440.	2.0	43
59	Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis. Journal of Cystic Fibrosis, 2015, 14, 763-769.	0.7	38
60	Clinical applications of pulmonary delivery of antibiotics. Advanced Drug Delivery Reviews, 2015, 85, 1-6.	13.7	46
61	Improvements in Lung Function and Height among Cohorts of 6-Year-Olds with Cystic Fibrosis from 1994 to 2012. Journal of Pediatrics, 2014, 165, 1091-1097.e2.	1.8	24
62	Anti-PcrV antibody in cystic fibrosis: A novel approach targeting Pseudomonas aeruginosa airway infection. Pediatric Pulmonology, 2014, 49, 650-658.	2.0	90
63	The challenge of improving outcomes for patients with CF sinonasal disease. Journal of Cystic Fibrosis, 2014, 13, 361-362.	0.7	1
64	Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995â€“2005. Journal of Cystic Fibrosis, 2013, 12, 332-337.	0.7	18
65	Evidence of diminished FEV1 and FVC in 6-year-olds followed in the European cystic fibrosis patient registry, 2007â€“2009. Journal of Cystic Fibrosis, 2013, 12, 786-789.	0.7	8
66	Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatric Pulmonology, 2013, 48, 666-673.	2.0	99
67	Decade-long bacterial community dynamics in cystic fibrosis airways. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5809-5814.	7.1	543
68	Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease. Clinical Investigation, 2012, 2, 163-175.	0.0	31
69	Microbial diversity in the cystic fibrosis airways: where is thy sting?. Future Microbiology, 2012, 7, 801-803.	2.0	18
70	Risk factors for rate of decline in FEV1 in adults with cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 405-411.	0.7	96
71	Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?. Respiratory Medicine, 2011, 105, S9-S17.	2.9	21
72	Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis. Respiratory Medicine, 2011, 105, S18-S23.	2.9	14

#	Article	IF	Citations
73	Tobramycin administered by the TOBI® Podhaler® for persons with cystic fibrosis: a review. Medical Devices: Evidence and Research, 2011, 4, 179.	0.8	50
74	Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. Pediatric Pulmonology, 2010, 45, 1156-1166.	2.0	39
75	Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatric Pulmonology, 2010, 45, 1167-1172.	2.0	58
76	Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respiratory Research, 2010, 11, 137.	3.6	53
77	Characterizing aggressiveness and predicting future progression of CF lung disease. Journal of Cystic Fibrosis, 2009, 8, S15-S19.	0.7	52
78	Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. Pediatric Pulmonology, 2008, 43, 739-744.	2.0	21
79	How much doPseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis?. Pediatric Pulmonology, 2005, 39, 504-506.	2.0	50
80	First Bacterial Infection as an Alternative Clinical End Point for Regulatory Approval of Agents Targeting the Primary Cystic Fibrosis Defect. Journal of Pediatrics, 2005, 147, 332-334.	1.8	0
81	Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatric Pulmonology, 2004, 38, 314-320.	2.0	116
82	Determination of polymyxin E1 in rat plasma by high-performance liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 789, 365-372.	2.3	20
83	A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 2000, 405, 962-966.	27.8	971
84	Electrophoretic isolation of extrachromosomal DNA from tumor cells. Genes Chromosomes and Cancer, 1995, 12, 262-271.	2.8	1
85	Y chromosome loss in chronic myeloid leukemia detected in both normal and malignant cells by interphase fluorescence in situ hybridization. Genes Chromosomes and Cancer, 1994, 11, 141-145.	2.8	22
86	Resolution of DNA fragments from 23 kilobases to 6 megabases by biphasic linear pulse ramping. Nucleic Acids Research, 1992, 20, 1148-1148.	14.5	7
87	Trisomy 8 in primary esthesioneuroblastoma. Cancer Genetics and Cytogenetics, 1991, 57, 133-136.	1.0	30
88	Cystic fibrosis: definition, severity and impact of pulmonary exacerbations. , 0, , 25-37.		0